Cantor Fitzgerald reiterated their hold rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research report released on Monday morning. Cantor Fitzgerald currently has a $17.00 price objective on the stock.

Several other equities research analysts also recently weighed in on TEVA. Jefferies Group LLC reiterated a hold rating and set a $26.00 target price (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Maxim Group reiterated a hold rating and set a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Deutsche Bank AG reiterated a buy rating and set a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. UBS AG reiterated a neutral rating and set a $19.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, September 14th. Finally, Sanford C. Bernstein downgraded shares of Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating and decreased their target price for the stock from $42.00 to $28.00 in a research note on Friday, August 4th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has an average rating of Hold and a consensus target price of $31.20.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.677% during trading on Monday, hitting $17.105. The company’s stock had a trading volume of 15,511,351 shares. The company has a 50-day moving average of $18.56 and a 200 day moving average of $28.33. The firm’s market cap is $17.38 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $51.51. Teva Pharmaceutical Industries Limited also was the target of unusually large options trading activity on Monday. Investors acquired 20,895 put options on the stock. This represents an increase of approximately 103% compared to the typical volume of 10,273 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the company posted $1.25 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/19/teva-pharmaceutical-industries-limited-teva-receives-hold-rating-from-cantor-fitzgerald.html.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were given a $0.085 dividend. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 2.00%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Greylin Investment Mangement Inc. boosted its position in Teva Pharmaceutical Industries Limited by 36.9% during the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock worth $9,783,000 after acquiring an additional 79,300 shares during the last quarter. PGGM Investments boosted its position in Teva Pharmaceutical Industries Limited by 12.0% during the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after acquiring an additional 163,292 shares during the last quarter. Financial Counselors Inc. boosted its position in Teva Pharmaceutical Industries Limited by 5.7% during the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after acquiring an additional 7,571 shares during the last quarter. GAM Holding AG boosted its position in Teva Pharmaceutical Industries Limited by 23.2% during the second quarter. GAM Holding AG now owns 41,900 shares of the company’s stock worth $1,392,000 after acquiring an additional 7,900 shares during the last quarter. Finally, Bank Hapoalim BM boosted its position in Teva Pharmaceutical Industries Limited by 9.2% during the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after acquiring an additional 980 shares during the last quarter. Hedge funds and other institutional investors own 56.76% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.